265 related articles for article (PubMed ID: 25352325)
1. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
Avigan MI; Bjornsson ES; Pasanen M; Cooper C; Andrade RJ; Watkins PB; Lewis JH; Merz M
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S19-31. PubMed ID: 25352325
[TBL] [Abstract][Full Text] [Related]
2. Causality assessment for suspected DILI during clinical phases of drug development.
Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
[TBL] [Abstract][Full Text] [Related]
3. Liver safety assessment in special populations (hepatitis B, C, and oncology trials).
Kullak-Ublick GA; Merz M; Griffel L; Kaplowitz N; Watkins PB
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S57-62. PubMed ID: 25352328
[TBL] [Abstract][Full Text] [Related]
4. Methodology to assess clinical liver safety data.
Merz M; Lee KR; Kullak-Ublick GA; Brueckner A; Watkins PB
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S33-45. PubMed ID: 25352326
[TBL] [Abstract][Full Text] [Related]
5. DILI and drug development: a regulatory perspective.
Avigan MI
Semin Liver Dis; 2014 May; 34(2):215-26. PubMed ID: 24879985
[TBL] [Abstract][Full Text] [Related]
6. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges.
Senior JR
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S9-17. PubMed ID: 25352324
[TBL] [Abstract][Full Text] [Related]
7. FDA-approved drug labeling for the study of drug-induced liver injury.
Chen M; Vijay V; Shi Q; Liu Z; Fang H; Tong W
Drug Discov Today; 2011 Aug; 16(15-16):697-703. PubMed ID: 21624500
[TBL] [Abstract][Full Text] [Related]
8. Case definition and phenotype standardization in drug-induced liver injury.
Aithal GP; Watkins PB; Andrade RJ; Larrey D; Molokhia M; Takikawa H; Hunt CM; Wilke RA; Avigan M; Kaplowitz N; Bjornsson E; Daly AK
Clin Pharmacol Ther; 2011 Jun; 89(6):806-15. PubMed ID: 21544079
[TBL] [Abstract][Full Text] [Related]
9. Causality assessment in drug-induced liver injury.
Hayashi PH
Semin Liver Dis; 2009 Nov; 29(4):348-56. PubMed ID: 19826968
[TBL] [Abstract][Full Text] [Related]
10. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
Regev A; Palmer M; Avigan MI; Dimick-Santos L; Treem WR; Marcinak JF; Seekins D; Krishna G; Anania FA; Freston JW; Lewis JH; Sanyal AJ; Chalasani N
Aliment Pharmacol Ther; 2019 Mar; 49(6):702-713. PubMed ID: 30761572
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced liver injury and drug development: industry perspective.
Regev A
Semin Liver Dis; 2014 May; 34(2):227-39. PubMed ID: 24879986
[TBL] [Abstract][Full Text] [Related]
12. Idiosyncratic drug-induced liver injury: an update on the 2007 overview.
Hussaini SH; Farrington EA
Expert Opin Drug Saf; 2014 Jan; 13(1):67-81. PubMed ID: 24073714
[TBL] [Abstract][Full Text] [Related]
13. The application of metabonomics to predict drug-induced liver injury.
O'Connell TM; Watkins PB
Clin Pharmacol Ther; 2010 Sep; 88(3):394-9. PubMed ID: 20668441
[TBL] [Abstract][Full Text] [Related]
14. Latest advances in predicting DILI in human subjects: focus on biomarkers.
Hawkins MT; Lewis JH
Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1521-30. PubMed ID: 22998122
[TBL] [Abstract][Full Text] [Related]
15. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.
Fontana RJ; Seeff LB; Andrade RJ; Björnsson E; Day CP; Serrano J; Hoofnagle JH
Hepatology; 2010 Aug; 52(2):730-42. PubMed ID: 20564754
[TBL] [Abstract][Full Text] [Related]
16. Drug hepatotoxicity from a regulatory perspective.
Senior JR
Clin Liver Dis; 2007 Aug; 11(3):507-24, vi. PubMed ID: 17723917
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced liver injury.
Leise MD; Poterucha JJ; Talwalkar JA
Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
[TBL] [Abstract][Full Text] [Related]
18. Review article: Drug-induced liver injury--its pathophysiology and evolving diagnostic tools.
Au JS; Navarro VJ; Rossi S
Aliment Pharmacol Ther; 2011 Jul; 34(1):11-20. PubMed ID: 21539586
[TBL] [Abstract][Full Text] [Related]
19. Current challenges and controversies in drug-induced liver injury.
Corsini A; Ganey P; Ju C; Kaplowitz N; Pessayre D; Roth R; Watkins PB; Albassam M; Liu B; Stancic S; Suter L; Bortolini M
Drug Saf; 2012 Dec; 35(12):1099-117. PubMed ID: 23137150
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced liver injury: what was new in 2013?
Chalhoub WM; Sliman KD; Arumuganathan M; Lewis JH
Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):959-80. PubMed ID: 24746272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
